VectorY Therapeutics Appoints Jessica Atkinson as Chief Business Officer to Advance Neurodegenerative Disease Pipeline
VectorY Therapeutics, a biotechnology company developing vectorized antibody therapies for neurodegenerative diseases, appointed Jessica Atkinson as Chief Business Officer in a newly created role.
Oligo Factory Expands Capabilities with New Low-Scale Synthesis Platform for Therapeutic and Diagnostic Development
Oligo Factory has launched a new low-scale oligonucleotide synthesis capability, enabling researchers to order custom DNA and RNA oligos in volumes as small as 50 nmol while maintaining high quality standards.
FDA Approves FoundationOne CDx as Companion Diagnostic for Tovorafenib in Pediatric Low-Grade Glioma
The FDA has approved FoundationOne CDx as a companion diagnostic for tovorafenib (Ojemda) in pediatric low-grade glioma (pLGG) patients with specific BRAF alterations.
Personalized Medicine Biomarkers Market Set to Reach $79.26 Billion by 2034, Driven by Precision Oncology and AI
The global personalized medicine biomarkers market is projected to grow from $21.95 billion in 2024 to $79.26 billion by 2034, representing a CAGR of 13.7% as demand for precision healthcare solutions increases.
FDA Approves FoundationOne Liquid CDx as Companion Diagnostic for Tepotinib in NSCLC
The FDA has approved FoundationOne Liquid CDx as a companion diagnostic for tepotinib in metastatic non-small cell lung cancer (NSCLC) patients with MET exon 14 skipping alterations.
FDA Approves FoundationOne Liquid CDx as Companion Diagnostic for Tepotinib in METex14-Skipping NSCLC
The FDA has approved FoundationOne Liquid CDx as a companion diagnostic to identify metastatic non-small cell lung cancer (mNSCLC) patients with _MET_ exon 14 skipping alterations.
FDA Approves Companion Diagnostic for Tepotinib in mNSCLC with MET Exon 14 Skipping Alterations
The FDA approved FoundationOne Liquid CDx as a companion diagnostic for tepotinib, aiding in identifying mNSCLC patients with MET exon 14 skipping alterations.
FDA Approves FoundationOne Liquid CDx as Companion Diagnostic for Itovebi in PIK3CA-Mutated Breast Cancer
The FDA has approved FoundationOne Liquid CDx as a companion diagnostic for Itovebi (inavolisib) in combination with palbociclib and fulvestrant.
FDA Approves FoundationOne CDx and Liquid CDx as Companion Diagnostics for Olaparib Plus Abiraterone in BRCA-Mutated mCRPC
The FDA approved FoundationOne CDx and FoundationOne Liquid CDx as companion diagnostics for olaparib plus abiraterone for BRCA-mutated metastatic castration-resistant prostate cancer (mCRPC).